Status:
RECRUITING
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
Lead Sponsor:
RenJi Hospital
Conditions:
Oligometastatic Prostate Cancer
Eligibility:
MALE
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
In China, the incidence of prostate cancer is increasing in recent years, and it has ranked 5th among common male tumors and 1st in urinary tumors. Unlike developed countries in Europe and the United ...
Eligibility Criteria
Inclusion
- Age less than 75 years
- EORTC QLQC-30 score 2
- Life expectancy of 10 years
- Patients with oligometastatic prostate cancer on clinicopathological assessment
- Patients are suitable for radiotherapy and prostatectomy surgery
- Patients agree to participate in the study and sign the informed consent form before enrollment
Exclusion
- Tumor related fracture
- Cannot accept radiotherapy
- Visceral metastasis
- Serious infection
- Thromboembolism history
- Not effectively controlled cardiovascular complications
Key Trial Info
Start Date :
August 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2027
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06972511
Start Date
August 20 2023
End Date
December 30 2027
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RenJi hospital, school of Medicine, Shanghai Jiao Tong University
Shanghai, China, 200120